ReviewMedicine2025
Non-leprosy related dapsone hypersensitivity syndrome: A case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleDapsone is used for treating infectious and immunological disorders, but it may cause dapsone hypersensitivity syndrome (DHS), a serious concern for medical staff. However, in non-leprotic patients, the manifestations of DHS can be atypical and various, leading to diagnostic challenges and potential delays in treatment initiation, which requires attention. PATIENT CONCERNS: A 17-year-old Chinese male developed DHS after 3-week dapsone treatment for vasculitis, showing the risk of dapsone use in young patients. DIAGNOSIS: DHS symptoms include fever, rash, and lymphadenopathy, which can be life-threatening. Diagnosis for this patient was based on symptom recognition, medical history review, physical examination, and the link between dapsone intake and symptom onset.
interventionsOnce diagnosed, dapsone was withdrawn immediately. Corticosteroids were given to reduce inflammation, and antipyretics and anti-histamines were used for symptom relief. OUTCOMES: After treatment, the patient improved. Fever subsided quickly, the rash resolved in a week, and lymphadenopathy shrank. Follow-up showed full recovery with no symptom recurrence. LESSONS: This report details a case and reviews published cases of DHS. Summarizing their features aims to improve diagnostic accuracy and management strategies, thus helping healthcare providers handle similar cases better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.